- LogicBio Therapeutics, Inc. (LOGC) announced it is being acquired in a deal valued at about $68 million. These are the details.
LogicBio Therapeutics, Inc. (LOGC) announced that it has entered into a definitive agreement under which AstraZeneca (NASDAQ: AZN) Rare Disease will acquire LogicBio. This proposed acquisition brings LogicBio’s unique technology, experienced rare disease R&D team, and expertise in pre-clinical development to support Alexion’s growth in genomic medicines.
LogicBio developed technology platforms for the delivery and insertion of genes to address genetic diseases, as well as a platform designed to improve viral vector manufacturing processes. And these platforms, coupled with LogicBio’s highly experienced team and Alexion’s advancements with AstraZeneca, will drive future scientific possibilities and next-generation medicines to treat rare genetic diseases.
Under the terms of the agreement, Alexion, through a subsidiary, will initiate a cash tender offer to acquire all outstanding shares of LogicBio for $2.07 per share. And both boards have unanimously approved the transaction. Alexion plans to close the deal in four to six weeks, subject to the tender of at least a majority of the outstanding shares of LogicBio common stock and satisfaction with other closing conditions and plans to retain LogicBio employees at their current location.
“We are excited about the opportunity to bring our science and expertise in genetic medicine to Alexion, which shares our commitment to discovering treatments for rare conditions and improving the lives of patients. Through this acquisition, we strive to accelerate our research in gene editing and AAV capsid development and together move the field of genomic medicine forward.”
— Fred Chereau, President and Chief Executive Officer, LogicBio
“The proposed acquisition of LogicBio is a significant development for our growing research in genomic medicine. LogicBio’s people, experience and platforms provide new scientific capabilities by adding best-in-class technology and expertise to our genomic medicine strategy. The scientific collaboration between Alexion and AstraZeneca has been a substantial area of focus since last year’s acquisition and the addition of LogicBio will expand this foundational work.”
— Marc Dunoyer, Chief Executive Officer, Alexion, AstraZeneca Rare Disease